Regen BioPharma, Inc. Files New Composition of Matter Patent Application Based on Its Successful Modulation of NR2F6 by Its Small Molecule Compounds
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has filed a patent application covering composition of matter and methods of use related to…
Regen BioPharma, Inc. Reports Success of its NR2F6 Small Molecule Screening Program for Treating Autoimmune Diseases
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), has identified a series of small molecule drugs that inhibit NR2F6. Regen’s screening process…
No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist
Regen BioPharma Inc.’s (OTCQB: RGBP) and (OTCQB: RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed…
No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist
Regen BioPharma Inc.’s (OTCQB: RGBP) and (OTCQB: RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed…
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6 nuclear…
Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has moved into the second stage of its previously-announced program to determine the…
Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has moved into the second stage of its previously-announced program to determine the three-dimensional structure of NR2F6 – with and without its proprietary small molecule drugs bound to it. The object of this structure-determination program is to shed light on how the small molecules bind to and […]
Regen BioPharma, Inc.’s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company’s contract research organization.
Regen BioPharma, Inc.’s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key…
Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the Company’s NR2F6 small molecule agonists in live rats and in tissues derived from humans and rats. Key attributes that are being measured include pH, plasma and liver microsomal stability, along with […]